Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
TransMedics Group (TMDX) remains a Sell due to high valuation and decelerating revenue growth despite recent earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback